Position in PHAT
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$2,033,130
-$1,298,523 QoQ
Shares Held
183,000
-8.9% QoQ
Ownership
0.229%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PHAT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026NewEdge Advisors, LLC holds $33,544,403 across 116 Biotechnology names. PHAT ranks #4 (6.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
17,146 | $7,656,374 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,610 | $5,879,790 | |
| 3 | NUVB |
Nuvation Bio Inc.
|
1,031,112 | $4,423,470 | |
| 4 | PHAT |
Phathom Pharmaceuticals, Inc.
This page
|
183,000 | $2,033,130 | |
| 5 | INCY |
Incyte Corp
|
20,416 | $1,921,553 | |
| 6 | EXEL |
Exelixis, Inc.
|
33,985 | $1,457,616 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
24,351 | $1,375,587 | |
| 8 | INSM |
INSMED Inc
|
6,015 | $983,572 |
All Filings in PHAT
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,033,130 | 183,000 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $3,331,653 | 200,823 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $2,371,925 | 201,523 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||